The possible role of an adrenergic mechanism in the antianginal action of papaverine and prenylamine.
D000787:Angina Pectoris / Q000188:drug therapy; D000818:Animals; D001795:Blood Pressure Determination; D003331:Coronary Vessels / Q000187:drug effects; D003864:Depression, Chemical; D004285:Dogs; D004336:Drug Antagonism; D004983:Ethanolamines / Q000494:pharmacology; D005260:Female; D006321:Heart / Q000187:drug effects; D008297:Male; D010101:Oxygen Consumption / Q000187:drug effects; D010208:Papaverine / Q000494:pharmacology*; D010477:Perfusion; D011299:Prenylamine / Q000494:pharmacology*; D011433:Propranolol / Q000494:pharmacology; D011955:Receptors, Drug; D013268:Stimulation, Chemical; D013565:Sympatholytics / Q000494:pharmacology*; D013566:Sympathomimetics / Q000494:pharmacology*; D014665:Vasodilator Agents / Q000494:pharmacology
D004983:Ethanolamines; D011955:Receptors, Drug; D013565:Sympatholytics; D013566:Sympathomimetics; D014665:Vasodilator Agents; D011433:Propranolol; D010208:Papaverine; D011299:Prenylamine